Thus, although TAM and aromatase inhibitors are effective and have been widely used to treat ER+ breast cancer, determining the appropriate level of ERα suppression and exploring the balance of the ER expression in the tumor microenvironment is required. Here, CYP19A1 is linked to breast carcinoma.